查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997463

代謝體學市場：按成分、適應症、應用和最終用戶分類－2026-2032年全球市場預測

Metabolomics Market by Component, Indication, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，代謝體學市場價值將達到 33.9 億美元，到 2026 年將成長至 37.8 億美元，到 2032 年將達到 73.9 億美元，複合年成長率為 11.76%。

主要市場統計數據
基準年 2025 33.9億美元
預計年份：2026年 37.8億美元
預測年份 2032 73.9億美元
複合年成長率 (%) 11.76%

隨著科學技術的進步，代謝體學正在發展成為一種系統級能力，對生物醫學和環境領域的應用產生了革命性的影響。

隨著研究人員和行業相關人員對小分子表現型及其轉化應用的深入探索，代謝體學領域正日益受到關注。分析儀器和計算能力的最新進展使得在複雜的生物基質中進行更全面、更可重複的代謝物分析成為可能。這些進展正在重塑實驗設計，加速生物標記的發現，並拓展代謝體學在藥物研發、臨床研究、環境監測和營養科學等領域的實際應用。因此，各機構正在重新評估自身將高解析度檢測平台與強大的生物資訊流程結合的能力。

分析儀器、分離化學和雲生物資訊學的進步正在推動代謝體學向以轉化醫學為重點的協作生態系統發展。

一場變革性的轉變正在發生，它正在重新定義代謝體學的實踐、資金籌措和商業化方式。在技術水準，質譜靈敏度和解析度的提高、核磁共振波譜在無損分析中的廣泛應用以及新型表面質譜方法的出現，都提高了代謝物檢測和鑑定的可靠性。同時，從毛細管電泳到高效液相層析等分離化學技術的改進，正在提升異構體分離能力，降低基質效應，進而提高數據品質和可解釋性。

美國不斷變化的關稅政策促使全球代謝體學企業調整其策略採購結構，制定供應鏈彈性計劃，並重組其合約。

近期源自美國的關稅政策對全球代謝體學供應鏈產生了多方面的影響，顯著影響了籌資策略、供應商選擇和成本結構。進口分析儀器和關鍵零件的關稅正在改變採購行為，促使實驗室延長儀器使用壽命，盡可能優先選擇本地供應商，或探索其他採購管道。這些行為變化對服務供應商和儀器製造商產生了後續影響，他們必須調整分銷策略和客戶支援模式，以維持市場准入和服務連續性。

多層分割揭示了成分選擇、適應症優先順序、應用重點和最終用戶需求如何結合起來，從而確定最佳的代謝體學和商業機會。

市場細分洞察闡明了技術選擇與最終用戶優先事項的交匯點，並驅動技術的應用路徑。基於組件，市場可分為生物資訊學工具和服務以及代謝體學儀器。在生物資訊領域，產品和服務種類繁多，從專用服務到獨立工具和資料庫，應有盡有。而儀器則分為檢測技術和分離平台。檢測技術包括質譜、核磁共振波譜和表面質譜，而分離平台則包括毛細管電泳、氣相層析法、高效液相層析和超高效液相層析。這種以組件為中心的觀點凸顯了買家通常更專注於整合的工作流程而非單一產品，他們要求檢測精確度和與下游資料處理的兼容性。

美洲、歐洲、中東和非洲以及亞太地區的不同區域趨勢，導致代謝體學利害關係人在實施路徑和夥伴關係策略方面出現分歧。

區域趨勢正在影響代謝體學系統中技術應用的速度、夥伴關係模式和投資重點。在美洲，成熟的學術網路和生物技術產業正在推動尖端檢測平台的快速普及，為提供專業代謝體學服務的受託研究機構（CRO）創造了強勁的市場。相較之下，歐洲、中東和非洲（EMEA）地區呈現出多元化的格局，領先的研究中心與優先考慮監管協調和跨境合作研究基礎設施的市場並存，從而推動了對可互通數據平台和標準化工作流程的需求。在亞太地區，生命科學領域的投資激增、臨床研究能力的提升以及國內製造能力的不斷發展，都為本地儀器生產和雲端生物資訊服務的應用創造了獎勵。

競爭優勢源自於硬體和軟體的整合創新、協作檢驗模型以及以服務為中心的方法，從而加速轉換可用性。

代謝體學領域的企業正透過檢測硬體、先進分離化學和整合生物資訊學服務的創新來打造差異化優勢，從而實現端到端的工作流程。其策略重點包括縮短結果獲取時間、提高代謝物註釋的可靠性以及在多中心研究中實現可擴展的資料管理。市場參與企業正投資於模組化平台，這些平台將高解析度檢測與靈活的分離選項相結合，使客戶能夠針對特定適應症（例如腫瘤學和神經病學研究）客製化分析方法。同時，軟體供應商正著重強調互通性、標準化報告格式和機器可讀的通路註釋，以加速轉換應用。

透過採用一體化的產品藍圖、區域服務擴展和協作檢驗框架，我們加速了各種用例的採用，並減少了實施摩擦。

行業領導者應優先考慮制定一套將儀器性能、分析和服務交付相結合的統一策略，以最大限度地提升價值。首先，調整產品藍圖，使檢測平台與分離模組和下游生物資訊工具實現內在相容性，可減少客戶整合過程中的阻力，並縮短引進週期。其次，投資於標準化的品質框架和可互通的數據導出，有助於促進多中心合作和監管互動，從而提高在臨床和環境應用中的可信度。第三，擴展區域服務基礎設施和本地化培訓項目，可以滿足美洲、歐洲、中東、非洲和亞太地區終端用戶的需求，同時緩解關稅相關的供應挑戰和物流延誤。

本研究採用嚴謹的混合方法，結合對關鍵相關人員的訪談、技術評估和文獻整合，為研究結果提供了支持，並檢驗了其可操作性。

本研究整合了系統性文獻回顧、針對性相關人員訪談、技術產品檢驗以及產業相關案例研究的證據，建構了代謝體學現狀的全面整體情況。第一階段包括對實驗室經理、設備專家、生物資訊學經理和採購經理進行結構化訪談，以確定實際限制因素和推廣應用促進因素。第二階段包括對同行評審文獻、監管指南、專利申請和技術白皮書進行精選審查，以檢驗技術聲明並識別新調查方法的發展趨勢。

策略重點放在互通性、檢驗夥伴關係和適應性經營模式上，將決定哪些組織能夠從代謝體學能力中獲得長期價值。

總而言之，代謝體學正透過先進檢測技術、精密的化學分離技術和可擴展的生物資訊學的融合，發展成為支持轉化研究、監管互動和環境監測的核心能力。這種成熟正在推動經營模式的演進，這些模式強調整合工作流程、服務交付和區域適應性。供應鏈的考量，包括關稅政策的影響和區域製造趨勢，在增加複雜性的同時，也為差異化服務交付和區域夥伴關係創造了機會。總而言之，可重複性、互通性和協作檢驗預示著未來，各組織將在提供基於代謝體學的洞見方面發揮主導。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章代謝體學市場：依成分分類

  • 生物資訊學工具和服務
    • 生物資訊服務
    • 生物資訊工具和資料庫
  • 代謝體學學設備
    • 檢測工具
      • 質譜分析
      • 核磁共振波譜
      • 表面質譜法
    • 分離工具
      • 毛細管電泳
      • 氣相層析法
      • 高效液相層析
      • 超高效液相層析

第9章：代謝體學市場：依適應症分類

  • 心血管疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤性疾病

第10章：代謝體學市場：依應用領域分類

  • 生物標記發現
    • 癌症生物標記
    • 神經系統生物標記
  • 藥物發現
    • 代謝途徑
    • 目標識別
  • 環境科學
    • 農藥殘留分析
    • 水質分析
  • 營養基因體學
    • 心血管健康
    • 肥胖調查
  • 個人化醫療
    • 基因組研究
    • 治療監測
  • 毒性測試

第11章代謝體學市場：依最終用戶分類

  • 學術研究機構
  • 合約研究機構
  • 製藥和生物技術公司

第12章代謝體學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章代謝體學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章代謝體學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國代謝體學市場

第16章：中國代謝體學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Afekta Technologies Ltd.
  • BASF SE
  • Bio-Rad Laboratories, Inc.
  • Biocrates Life Science AG
  • Bruker Corporation
  • Clinical Microbiomics A/S
  • Danaher Corporation
  • DNA Xperts Private Limited
  • General Metabolics
  • Hitachi High-Tech Corporation
  • Human Metabolome Technologies Inc.
  • JASCO Corporation
  • Kore Technology Limited
  • LECO Corporation
  • Merck KGaA
  • Metabolon, Inc.
  • Shimadzu Corporation
  • Techcomp Europe Ltd
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-50124643847C

The Metabolomics Market was valued at USD 3.39 billion in 2025 and is projected to grow to USD 3.78 billion in 2026, with a CAGR of 11.76%, reaching USD 7.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.39 billion
Estimated Year [2026] USD 3.78 billion
Forecast Year [2032] USD 7.39 billion
CAGR (%) 11.76%

An evolving scientific and technological landscape is elevating metabolomics into a systems-level capability with transformative implications for biomedical and environmental applications

The metabolomics landscape is experiencing heightened attention as researchers and commercial stakeholders pursue deeper understanding of small-molecule phenotypes and their translational applications. Over recent years, advances in analytical instrumentation and computational capacity have converged to enable more comprehensive, reproducible metabolite profiling across complex biological matrices. These developments are reshaping experimental design, accelerating biomarker discovery, and expanding the practical footprint of metabolomics within drug development, clinical research, environmental monitoring, and nutritional science. As a result, organizations are recalibrating capabilities to integrate high-resolution detection platforms with robust bioinformatics pipelines.

Concurrently, the field is maturing from a predominantly exploratory discipline toward one that supports regulated decision-making and clinical utility. The growing emphasis on standardization, quality control, and data interoperability has prompted investment in end-to-end workflows that join sample preparation, separation and detection, and downstream informatics. This integration creates opportunities for improved turnaround times, reproducibility, and cross-study comparability. Given this context, stakeholders should view metabolomics not simply as a technical specialty but as a systems-level capability that empowers precision approaches across therapeutic and environmental domains.

Converging advances in analytical instrumentation, separation chemistries, and cloud-enabled bioinformatics are reshaping metabolomics into a translationally focused and collaborative ecosystem

Transformative shifts are underway that are redefining how metabolomics is practiced, funded, and commercialized. At the technology level, improvements in mass spectrometry sensitivity and resolution, broader adoption of nuclear magnetic resonance spectroscopy for non-destructive profiling, and novel surface-based mass analysis approaches are expanding the detectability and confidence of metabolite identification. In parallel, the refinement of separation chemistries-ranging from capillary electrophoresis to ultra performance liquid chromatography-has enhanced the ability to resolve isomeric species and reduce matrix effects, thereby enriching data quality and interpretability.

On the data side, the integration of advanced bioinformatics tools and services with domain-specific databases is enabling scalable annotation and pathway mapping workflows that were previously prohibitive. The rise of modular, cloud-enabled bioinformatics tools and services is fostering collaborative analytics and reproducible pipelines across institutions. Organizationally, academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies are adopting hybrid models that blend in-house expertise with external service partners to accelerate time-to-insight. Taken together, these shifts are creating a more interoperable, translationally oriented ecosystem in which methodological rigor, data transparency, and cross-sector collaboration determine competitive advantage.

Evolving United States tariff measures are prompting strategic procurement adaptations, supply chain resilience planning, and contract restructuring across global metabolomics operations

Recent tariff policies originating from the United States have produced a multifaceted set of effects across global metabolomics supply chains, with notable implications for procurement strategies, vendor selection, and cost structures. Tariffs that affect imported analytical instruments and key components can alter purchasing behavior, prompting laboratories to extend equipment lifecycles, prioritize local vendors where feasible, or seek alternative procurement channels. These behavioral responses have downstream consequences for service providers and instrument manufacturers who must adapt distribution strategies and customer support models to maintain market access and service continuity.

Beyond procurement, tariff-driven shifts influence collaboration patterns. Academic research institutes and contract research organizations that operate cross-border projects may encounter increased administrative overhead and logistical complexity when sourcing specialized consumables or replacement parts. As a consequence, partnerships that emphasize local manufacturing, in-region servicing, and pre-emptive spare-part inventories gain attractiveness. Moreover, regulatory compliance and customs-related delays can impact study timelines, necessitating contingency planning in project design. Collectively, these dynamics underscore the importance of supply chain resilience and proactive contractual terms when conducting metabolomics research in an environment shaped by evolving trade policies.

Layered segmentation reveals how component choices, indication priorities, application focus, and end-user needs jointly determine optimal metabolomics workflows and commercial opportunities

Insight into market segmentation clarifies where technology choices and end-user priorities intersect to drive adoption pathways. Based on component, the landscape divides between bioinformatics tools and services and metabolomic instruments; within bioinformatics, offerings span dedicated services and standalone tools and databases, while instruments separate into detection technologies and separation platforms, with detection including mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis and separation encompassing capillary electrophoresis, gas chromatography, high-performance liquid chromatography, and ultra performance liquid chromatography. This component-oriented view highlights that purchasers often evaluate integrated workflows rather than discrete products, seeking compatibility between detection fidelity and downstream data processing.

Based on indication, the workstreams concentrate on cardiovascular disorders, metabolic disorders, neurological disorders, and oncological disorders, each of which places distinct demands on sensitivity, longitudinal sampling, and biomarker validation strategies. Based on application, efforts cluster around biomarker discovery, drug discovery, environmental science, nutrigenomics, personalized medicine, and toxicology testing, with biomarker discovery further differentiating into cancer and neurological biomarker initiatives and drug discovery emphasizing metabolic pathway elucidation and target identification; environmental science applications prioritize pesticide residue and water quality analysis while nutrigenomics focuses on cardiovascular health and obesity research and personalized medicine addresses genomic studies and therapeutic monitoring. Based on end-user, the primary consumers include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, and each user group balances different trade-offs between throughput, regulatory readiness, and cost-efficiency. Understanding these layered segmentations enables targeted solution design that aligns analytical capability with clinical or environmental validation requirements.

Distinct regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific create differentiated adoption pathways and partnership strategies for metabolomics stakeholders

Regional dynamics shape technology adoption rhythms, partnership models, and investment priorities across the metabolomics ecosystem. In the Americas, established academic networks and a mature biotechnology industry foster rapid uptake of cutting-edge detection platforms and a strong market for contract research organizations that provide specialized metabolomics services. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape in which centers of excellence coexist with markets prioritizing regulatory harmonization and cross-border collaborative research infrastructures, driving demand for interoperable data platforms and standardized workflows. In the Asia-Pacific region, high growth in life sciences investment, expanding clinical research capacity, and evolving domestic manufacturing capabilities create incentives for both local instrument production and adoption of cloud-enabled bioinformatics services.

These regional patterns influence vendor strategies for product localization, training, and after-sales support. They also affect the design of clinical studies and environmental monitoring programs, as regional regulatory expectations and sampling infrastructures differ. Consequently, organizations must develop adaptive market entry plans that reflect local end-user preferences, talent availability, and distribution networks while leveraging global partnerships to ensure access to specialized detection technologies and advanced informatics.

Competitive differentiation emerges from integrated hardware and software innovation, collaborative validation models, and service-centric approaches that accelerate translational utility

Companies operating in the metabolomics space are differentiating through innovation in detection hardware, enhanced separation chemistries, and integrated bioinformatics services that facilitate end-to-end workflows. Strategic priorities include reducing time-to-result, improving metabolite annotation confidence, and enabling scalable data management across multi-site studies. Market participants are investing in modular platforms that pair high-resolution detection with flexible separation options, thereby allowing customers to tailor analytical approaches to specific indications such as oncology or neurological research. Simultaneously, software providers are emphasizing interoperability, standardized reporting formats, and machine-readable pathway annotations to accelerate translational use.

Partnership models are evolving to emphasize co-development with academic consortia and clinical networks, which expedites the validation of biomarkers and the alignment of analytical protocols with clinical endpoints. Service providers and instrument developers are also placing greater emphasis on training and on-site support offerings to lower barriers to adoption. From an operational standpoint, organizations that maintain robust global service footprints, resilient supply chains, and configurable finance options for capital equipment are better positioned to support diverse customer segments. These strategic orientations collectively shape competitive dynamics and determine which entities can sustainably scale across research and commercial applications.

Adopt integrated product roadmaps, regional service expansion, and collaborative validation frameworks to accelerate adoption and reduce implementation friction across diverse use cases

Industry leaders should prioritize cohesive strategies that bridge instrument performance with analytics and service delivery to maximize value capture. First, aligning product roadmaps so that detection platforms are inherently compatible with separation modules and downstream bioinformatics tools will reduce integration friction for customers and shorten adoption cycles. Second, investing in standardized quality frameworks and interoperable data exports will facilitate multi-site studies and regulatory interactions, thereby increasing credibility for clinical and environmental applications. Third, expanding regional service infrastructures and localized training programs will address end-user needs in the Americas, Europe Middle East & Africa, and Asia-Pacific while mitigating tariff-related supply challenges and logistical delays.

Additionally, organizations should pursue strategic collaborations with academic centers and contract research organizations to validate use cases across cardiovascular, metabolic, neurological, and oncological indications. Companies will benefit from offering modular commercial models that encompass instrument-as-a-service, consumable subscriptions, and bespoke analytics engagements tailored to biomarker discovery, drug discovery, nutrigenomics, personalized medicine, environmental science, and toxicology testing. Finally, enhancing transparency around data provenance and analytical uncertainty will build trust with clinical partners and regulators and will support broader adoption of metabolomics-derived decision tools.

A rigorous mixed-methods approach combining primary stakeholder interviews, technical assessments, and literature synthesis underpins the findings and validates practical implications

This research synthesizes evidence from systematic literature reviews, targeted stakeholder interviews, technical product assessments, and cross-validation of industry-relevant case studies to construct a robust portrait of the metabolomics landscape. Primary research involved structured interviews with laboratory directors, instrumentation specialists, bioinformatics leads, and procurement managers to capture practical constraints and adoption drivers. Secondary research entailed a curated review of peer-reviewed literature, regulatory guidance, patent filings, and technology white papers to validate technical assertions and identify emerging methodological trends.

Analytical approaches included technology readiness assessments, workflow mapping to identify integration bottlenecks, and qualitative triangulation of vendor claims against independent academic evaluations. Data quality protocols emphasized reproducibility checks, expert validation panels, and iterative synthesis to ensure that conclusions reflect both operational realities and scientific rigor. Where appropriate, confidential supplier disclosures and anonymized project data were used to corroborate service delivery models and supportability claims, with findings distilled into actionable implications for practitioners, investors, and policy stakeholders.

A strategic focus on interoperability, validation partnerships, and adaptive commercial models will determine which organizations capture long-term value from metabolomics capabilities

In summary, metabolomics is transitioning into a core capability that supports translational research, regulatory engagement, and environmental monitoring through the convergence of advanced detection technologies, refined separation chemistries, and scalable bioinformatics. This maturation is accompanied by evolving commercial models that emphasize integrated workflows, service delivery, and regional adaptability. Supply chain considerations, including the effects of tariff policy and regional manufacturing trends, add complexity but also create opportunities for differentiated service offerings and local partnerships. Taken together, these forces point to a future in which reproducibility, interoperability, and collaborative validation will determine which organizations lead in delivering metabolomics-driven insights.

For stakeholders, the imperative is clear: invest in interoperable platforms, prioritize partnerships that accelerate clinical validation, and design commercial models that reduce implementation friction for end-users across academic, contract research, and pharmaceutical and biotechnology settings. By doing so, organizations can harness metabolomics to generate robust biological insights that meaningfully inform research, product development, and regulatory decision-making.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Metabolomics Market, by Component

  • 8.1. Bioinformatics Tools & Services
    • 8.1.1. Bioinformatics Services
    • 8.1.2. Bioinformatics Tools & Databases
  • 8.2. Metabolomic Instruments
    • 8.2.1. Detection Tools
      • 8.2.1.1. Mass Spectrometry
      • 8.2.1.2. Nuclear Magnetic Resonance Spectroscopy
      • 8.2.1.3. Surface-based Mass Analysis
    • 8.2.2. Separation Tools
      • 8.2.2.1. Capillary Electrophoresis
      • 8.2.2.2. Gas Chromatography
      • 8.2.2.3. High-Performance Liquid Chromatography
      • 8.2.2.4. Ultra Performance Liquid Chromatography

9. Metabolomics Market, by Indication

  • 9.1. Cardiovascular Disorders
  • 9.2. Metabolic Disorders
  • 9.3. Neurological Disorders
  • 9.4. Oncological Disorders

10. Metabolomics Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Cancer Biomarkers
    • 10.1.2. Neurological Biomarkers
  • 10.2. Drug Discovery
    • 10.2.1. Metabolic Pathways
    • 10.2.2. Target Identification
  • 10.3. Environmental Science
    • 10.3.1. Pesticide Residue Analysis
    • 10.3.2. Water Quality Analysis
  • 10.4. Nutrigenomics
    • 10.4.1. Cardiovascular Health
    • 10.4.2. Obesity Research
  • 10.5. Personalized Medicine
    • 10.5.1. Genomic Studies
    • 10.5.2. Therapeutic Monitoring
  • 10.6. Toxicology Testing

11. Metabolomics Market, by End-User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Metabolomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Metabolomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Metabolomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Metabolomics Market

16. China Metabolomics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Afekta Technologies Ltd.
  • 17.6. BASF SE
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Biocrates Life Science AG
  • 17.9. Bruker Corporation
  • 17.10. Clinical Microbiomics A/S
  • 17.11. Danaher Corporation
  • 17.12. DNA Xperts Private Limited
  • 17.13. General Metabolics
  • 17.14. Hitachi High-Tech Corporation
  • 17.15. Human Metabolome Technologies Inc.
  • 17.16. JASCO Corporation
  • 17.17. Kore Technology Limited
  • 17.18. LECO Corporation
  • 17.19. Merck KGaA
  • 17.20. Metabolon, Inc.
  • 17.21. Shimadzu Corporation
  • 17.22. Techcomp Europe Ltd
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METABOLOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL METABOLOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS METABOLOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. GCC METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. GCC METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 253. GCC METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 257. GCC METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. GCC METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. GCC METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 264. GCC METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 293. G7 METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. G7 METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 295. G7 METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 296. G7 METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. G7 METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 302. G7 METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 303. G7 METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 304. G7 METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 305. G7 METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 306. G7 METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 307. NATO METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 309. NATO METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 310. NATO METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 311. NATO METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 312. NATO METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 314. NATO METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. NATO METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 316. NATO METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 317. NATO METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 318. NATO METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 320. NATO METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 321. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES METABOLOMICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS,